. Gold, Global Strategy for the Diagnosis, Management and Prevention of COPD [Internet]. Global Initiative for Chronic Obstructive Lung Disease -GOLD. [cité 2 juin 2017]. Disponible sur: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd, 2017.

M. Divo, C. Cote, J. De-torres, C. Casanova, J. Marin et al., Comorbidities and Risk of Mortality in Patients with Chronic Obstructive Pulmonary Disease, American Journal of Respiratory and Critical Care Medicine, vol.11, issue.2, pp.155-61, 2012.
DOI : 10.1016/j.pcrj.2005.09.001

A. Patel, B. Kowlessar, G. Donaldson, A. Mackay, R. Singh et al., Cardiovascular Risk, Myocardial Injury, and Exacerbations of Chronic Obstructive Pulmonary Disease, American Journal of Respiratory and Critical Care Medicine, vol.185, issue.9, pp.1091-1100, 2013.
DOI : 10.1161/CIRCULATIONAHA.105.601641

L. Fabbri, F. Luppi, B. Beghé, and K. Rabe, Complex chronic comorbidities of COPD, European Respiratory Journal, vol.31, issue.1, pp.204-216, 2008.
DOI : 10.1183/09031936.00114307

URL : http://erj.ersjournals.com/content/erj/31/1/204.full.pdf

A. Agustí, L. Edwards, S. Rennard, W. Macnee, R. Tal-singer et al., Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype, PLoS ONE, vol.80, issue.5, p.37483, 2012.
DOI : 10.1371/journal.pone.0037483.s009

L. Vanfleteren, M. Spruit, E. Wouters, and F. Franssen, Management of chronic obstructive pulmonary disease beyond the lungs, The Lancet Respiratory Medicine, vol.4, issue.11, pp.911-935, 2016.
DOI : 10.1016/S2213-2600(16)00097-7

W. Chen, J. Thomas, M. Sadatsafavi, and J. Fitzgerald, Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis, The Lancet Respiratory Medicine, vol.3, issue.8, pp.631-640, 2015.
DOI : 10.1016/S2213-2600(15)00241-6

T. Ho, C. Huang, S. Ruan, Y. Tsai, F. Lai et al., Diabetes mellitus in patients with chronic obstructive pulmonary disease-The impact on mortality Disponible sur: https, PLoS ONE, vol.12, issue.4, p.2017, 2017.

I. Reccia, J. Kumar, C. Akladios, F. Virdis, M. Pai et al., Non-alcoholic fatty liver disease: A sign of systemic disease, Metabolism, vol.72, pp.94-108, 2017.
DOI : 10.1016/j.metabol.2017.04.011

L. Mathus-vliegen, Recommandations de Pratique Clinique de EASL?EASD-EASO sur la prise en charge de la stéatopathie métabolique, J Hepatol, vol.64, pp.1388-1402, 2016.

C. Bertot, L. Adams, and L. , The Natural Course of Non-Alcoholic Fatty Liver Disease Disponible sur: https, Int J Mol Sci, vol.17, issue.5, 2016.

L. Adams, J. Lymp, S. Sauver, J. Sanderson, S. Lindor et al., The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study, Gastroenterology, vol.129, issue.1, pp.113-134, 2005.
DOI : 10.1053/j.gastro.2005.04.014

Z. Younossi, A. Koenig, D. Abdelatif, Y. Fazel, L. Henry et al., Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes, Hepatology, vol.24, issue.1, pp.73-84, 2016.
DOI : 10.1111/j.1440-1746.2009.05831.x

URL : http://onlinelibrary.wiley.com/doi/10.1002/hep.28431/pdf

A. El-zayadi, Hepatic steatosis: A benign disease or a silent killer, World Journal of Gastroenterology, vol.14, issue.26, pp.4120-4126, 2008.
DOI : 10.3748/wjg.14.4120

URL : http://europepmc.org/articles/pmc2725370?pdf=render

M. Charlton, J. Burns, R. Pedersen, K. Watt, J. Heimbach et al., Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States, Gastroenterology, vol.141, issue.4, pp.1249-53, 2011.
DOI : 10.1053/j.gastro.2011.06.061

C. Byrne and G. Targher, NAFLD: A multisystem disease, Journal of Hepatology, vol.62, issue.1, pp.47-64, 2015.
DOI : 10.1016/j.jhep.2014.12.012

URL : https://doi.org/10.1016/j.jhep.2014.12.012

L. Bhatia, N. Curzen, P. Calder, and C. Byrne, Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?, European Heart Journal, vol.283, issue.10, pp.1190-200, 2012.
DOI : 10.1001/jama.283.15.2008

S. Francque, D. Van-der-graaff, and W. Kwanten, Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications, Journal of Hepatology, vol.65, issue.2, pp.425-443, 2016.
DOI : 10.1016/j.jhep.2016.04.005

A. Lonardo, S. Sookoian, C. Pirola, and G. Targher, Non-alcoholic fatty liver disease and risk of cardiovascular disease, Metabolism, vol.65, issue.8, pp.1136-50, 2016.
DOI : 10.1016/j.metabol.2015.09.017

P. Kanwar and K. Kowdley, The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis, Clinics in Liver Disease, vol.20, issue.2, pp.225-268, 2016.
DOI : 10.1016/j.cld.2015.10.002

C. Grander, F. Grabherr, A. Moschen, and H. Tilg, Non-Alcoholic Fatty Liver Disease: Cause or Effect of Metabolic Syndrome, Visceral Medicine, vol.32, issue.5, pp.329-363, 2016.
DOI : 10.1159/000448940

A. Lonardo, S. Bellentani, C. Argo, S. Ballestri, C. Byrne et al., Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups, Digestive and Liver Disease, vol.47, issue.12, pp.997-1006, 2015.
DOI : 10.1016/j.dld.2015.08.004

N. Chalasani, Z. Younossi, J. Lavine, A. Diehl, E. Brunt et al., The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology, Diseases, and American College of Gastroenterology, pp.1592-609, 2012.
DOI : 10.1053/j.gastro.2012.04.001

W. Gan, Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis, Thorax, vol.59, issue.7, pp.574-80, 2004.
DOI : 10.1136/thx.2003.019588

S. Selvarajah, I. Todd, P. Tighe, M. John, C. Bolton et al., Multiple Circulating Cytokines Are Coelevated in Chronic Obstructive Pulmonary Disease, Mediators of Inflammation, vol.13, issue.11, p.3604842, 2016.
DOI : 10.1371/journal.pone.0006053

URL : http://doi.org/10.1155/2016/3604842

X. Soler, E. Gaio, F. Powell, J. Ramsdell, J. Loredo et al., High Prevalence of Obstructive Sleep Apnea in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease, Ann Am Thorac Soc. août, vol.12, issue.8, pp.1219-1244, 2015.

E. Steveling, C. Clarenbach, D. Miedinger, C. Enz, S. Dürr et al., Predictors of the Overlap Syndrome and Its Association with Comorbidities in Patients with Chronic Obstructive Pulmonary Disease, Respiration, vol.88, issue.6, pp.451-458, 2014.
DOI : 10.1159/000368615

J. Aron-wisnewsky, K. Clement, and J. Pépin, Nonalcoholic fatty liver disease and obstructive sleep apnea, Metabolism, vol.65, issue.8, pp.1124-1159, 2016.
DOI : 10.1016/j.metabol.2016.05.004

URL : https://hal.archives-ouvertes.fr/hal-01346101

J. Aron-wisnewsky, C. Minville, J. Tordjman, P. Lévy, J. Bouillot et al., Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese, Journal of Hepatology, vol.56, issue.1, pp.225-258, 2012.
DOI : 10.1016/j.jhep.2011.04.022

C. Minville, M. Hilleret, R. Tamisier, J. Aron-wisnewsky, K. Clement et al., Nonalcoholic Fatty Liver Disease, Nocturnal Hypoxia, and Endothelial Function in Patients With Sleep Apnea, Chest, vol.145, issue.3, pp.525-558, 2014.
DOI : 10.1378/chest.13-0938

C. Baffi, L. Wood, D. Winnica, P. Strollo, M. Gladwin et al., Metabolic Syndrome and the Lung, Chest, vol.149, issue.6, pp.1525-1559, 2016.
DOI : 10.1016/j.chest.2015.12.034

B. Van-den-borst, H. Gosker, and A. Schols, Central Fat and Peripheral Muscle, American Journal of Respiratory and Critical Care Medicine, vol.34, issue.1, pp.8-13, 2013.
DOI : 10.1016/j.cell.2012.01.017

K. Lam, R. Jordan, C. Jiang, G. Thomas, M. Miller et al., Airflow obstruction and metabolic syndrome: the Guangzhou Biobank Cohort Study, European Respiratory Journal, vol.35, issue.2, pp.317-340, 2010.
DOI : 10.1183/09031936.00024709

URL : http://erj.ersjournals.com/content/erj/35/2/317.full.pdf

D. Viglino, I. Jullian-desayes, M. Minoves, J. Aron-wisnewsky, V. Leroy et al., Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease, European Respiratory Journal, vol.49, issue.6, p.1601923, 2017.
DOI : 10.1183/13993003.01923-2016.Supp1

M. Munteanu, V. Ratziu, R. Morra, D. Messous, F. Imbert-bismut et al., Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience, J Gastrointestin Liver Dis, vol.17, issue.2, pp.187-91, 2008.

R. Morra, M. Munteanu, F. Imbert-bismut, D. Messous, V. Ratziu et al., FibroMAX???: towards a new universal biomarker of liver disease?, Expert Review of Molecular Diagnostics, vol.22, issue.5, pp.481-90, 2007.
DOI : 10.1016/0168-8278(95)80226-6

V. Ratziu, J. Massard, C. F. Messous, D. Imbert-bismut, F. Bonyhay et al., Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease, BMC Gastroenterology, vol.277, issue.1, p.6, 2006.
DOI : 10.1074/jbc.M107771200

D. Kleiner, E. Brunt, M. Van-natta, C. Behling, M. Contos et al., Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, vol.38, issue.6, pp.1313-1334, 2005.
DOI : 10.1002/hep.20701

T. Poynard, V. Ratziu, S. Naveau, D. Thabut, C. F. Messous et al., The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis, Comparative Hepatology, vol.4, issue.1, p.10, 2005.
DOI : 10.1186/1476-5926-4-10

Q. Anstee, G. Targher, and C. Day, Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis, Nature Reviews Gastroenterology & Hepatology, vol.31, issue.6, pp.330-374, 2013.
DOI : 10.1055/s-0031-1276643

G. Targher, C. Day, and E. Bonora, Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease, New England Journal of Medicine, vol.363, issue.14, pp.1341-50, 2010.
DOI : 10.1056/NEJMra0912063

G. Targher, C. Byrne, A. Lonardo, G. Zoppini, and C. Barbui, Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis, Journal of Hepatology, vol.65, issue.3, pp.589-600, 2016.
DOI : 10.1016/j.jhep.2016.05.013

P. Angulo, D. Kleiner, S. Dam-larsen, L. Adams, E. Bjornsson et al., Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease, Gastroenterology, vol.149, issue.2, pp.389-397, 2015.
DOI : 10.1053/j.gastro.2015.04.043

URL : http://europepmc.org/articles/pmc4516664?pdf=render

H. Müllerova, A. Agusti, S. Erqou, and D. Mapel, Cardiovascular Comorbidity in COPD: Systematic Literature Review. Chest. 1 oct, vol.144, issue.4, pp.1163-78, 2013.

G. Donaldson, T. A. Seemungal, A. Bhowmik, and J. Wedzicha, Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease, Thorax, vol.57, issue.10, pp.847-52, 2002.
DOI : 10.1136/thorax.57.10.847

J. Feary, L. Rodrigues, C. Smith, R. Hubbard, and J. Gibson, Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care, Thorax, vol.65, issue.11, pp.956-62, 2010.
DOI : 10.1136/thx.2009.128082

A. Diaz, T. Young, S. Kurugol, E. Eckbo, N. Muralidhar et al., Abdominal Visceral Adipose Tissue is Associated with Myocardial Infarction in Patients with COPD, Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation, vol.2, issue.1, pp.8-16
DOI : 10.15326/jcopdf.2.1.2015.0127

J. Garcia-aymerich, F. Gómez, M. Benet, E. Farrero, X. Basagaña et al., Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes, Thorax, vol.66, issue.5, pp.430-437, 2011.
DOI : 10.1136/thx.2010.154484

A. Zhou, Z. Zhou, Y. Zhao, and P. Chen, The recent advances of phenotypes in acute exacerbations of COPD, International Journal of Chronic Obstructive Pulmonary Disease, vol.12, 2017.
DOI : 10.2147/COPD.S128604

F. Blasi, L. Neri, S. Centanni, F. Falcone, and G. Maria, Clinical Characterization and Treatment Patterns for the Frequent Exacerbator Phenotype in Chronic Obstructive Pulmonary Disease with Severe or Very Severe Airflow Limitation, COPD: Journal of Chronic Obstructive Pulmonary Disease, vol.42, issue.57, pp.15-22, 2017.
DOI : 10.4104/pcrj.2013.00016

N. Lipovec, R. Beijers, B. Borst, . Van-den, W. Doehner et al., The Prevalence of Metabolic Syndrome In Chronic Obstructive Pulmonary Disease: A Systematic Review, COPD: Journal of Chronic Obstructive Pulmonary Disease, vol.3, issue.1, pp.399-406, 2016.
DOI : 10.2337/diacare.28.9.2289

V. Koblizek, B. Milenkovic, A. Barczyk, R. Tkacova, A. Somfay et al., Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE Study Disponible sur: https, Eur Respir J [Internet], vol.49, issue.5

M. Divo, C. Casanova, J. Marin, V. Pinto-plata, J. De-torres et al., COPD comorbidities network Eur Respir J. sept, vol.46, issue.3, pp.640-50, 2015.

S. Curkendall, C. Jones, J. Lanes, S. Stang, M. Goehring et al., Cardiovascular Disease in Patients with Chronic Obstructive Pulmonary Disease, Saskatchewan Canada, Annals of Epidemiology, vol.16, issue.1, pp.63-70, 2006.
DOI : 10.1016/j.annepidem.2005.04.008

C. Echevarria, J. Steer, K. Heslop-marshall, S. Stenton, P. Hickey et al., Validation of the DECAF score to predict hospital mortality in acute exacerbations of COPD, Thorax, vol.32, issue.(Suppl 6), pp.133-173, 2016.
DOI : 10.1183/09031936.00129507

J. Steer, J. Gibson, and S. Bourke, The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease, Thorax, vol.67, issue.11, pp.970-976, 2012.
DOI : 10.1136/thoraxjnl-2012-202103

V. Athyros, T. Alexandrides, H. Bilianou, E. Cholongitas, M. Doumas et al., The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement, Metabolism, vol.71, pp.17-32, 2017.
DOI : 10.1016/j.metabol.2017.02.014

A. Scherer and J. Dufour, Treatment of Non-Alcoholic Fatty Liver Disease, Digestive Diseases, vol.34, issue.1, pp.27-31, 2016.
DOI : 10.1159/000447278